Welcome to Makai Biotechnology

Makai Biotechnology is developing novel therapies for the treatment of heart failure.

A new ion channel target in this disease has been identified, along with multiple effective compounds that regulate this target.

We are establishing alliances with major pharmaceutical companies to develop and test compounds from pre-clinical through to phase II clinical trials.


• February 2015 -

Edward Jay Wilusz joins Makai Bio as Senior Vice President of IP Strategy and Licensing

Mr. Wilusz joins Makai Bio, with over 20 years experience in pharmaceutical asset development, marketing, and licensing. He will be an invaluable component in the development of Makai Bio.

April 2014 -

Makai Bio and University of Hawaii

Makai Bio partners with University of Hawaii to develop a new cardiovascular therapeutic aimed to treat and prevent heart failure.